欧盟限制中国医疗器材进口，商务部：坚决反对，望欧方纠正错误做法

Core Viewpoint - The European Union (EU) has decided to restrict Chinese medical device imports under the International Procurement Instrument (IPI) to counter perceived discrimination against foreign manufacturers in public procurement by Beijing [1][2]. Group 1: EU's Decision and Implications - The EU's decision prohibits Chinese companies from participating in public tender projects for medical devices valued over 5 million euros for the next five years [1]. - The EU China Chamber of Commerce expressed deep disappointment and concern over this decision, stating that it contradicts the principles of open markets and fair competition [1][2]. - The IPI is viewed as a unilateral tool by the EU, which may exacerbate the complexity of EU-China economic relations [1][2]. Group 2: Background and Context - The IPI was introduced in 2022 to allow the EU to investigate non-EU companies and impose restrictions on their market access, particularly targeting emerging economies like China [2]. - The EU initiated a nine-month investigation into public procurement in the Chinese medical device sector under the IPI, marking the first use of this regulation [2]. Group 3: Reactions and Future Negotiations - The EU China Chamber of Commerce highlighted that the EU's pursuit of "market equality" fails to consider the historical context, as European medical device companies have benefited from significant market access in China [3]. - There remains a possibility for an agreement between the EU and China to avoid further measures, with EU Trade Commissioner Valdis Dombrovskis indicating a willingness to negotiate [3]. - The Chinese Ministry of Commerce firmly opposes the EU's discriminatory measures, emphasizing the need for fair competition and warning of potential retaliatory actions [3].